Key result
Ramosetron was superior to ondansetron and comparable to ondansetron for the prevention of postoperative nausea and vomiting after laparoscopic surgery.
Why the study?
The comparative efficacy and safety of ramosetron versus ondansetron for preventing postoperative nausea and vomiting in patients undergoing laparoscopic surgery required systematic evaluation.
Does ramosetron reduce postoperative nausea and vomiting compared to ondansetron in patients undergoing laparoscopic surgery?
Meta-Analysis
Does ramosetron reduce postoperative nausea and vomiting compared to ondansetron in patients undergoing laparoscopic surgery?
Ramosetron 0.3 mg is superior to ondansetron 4 mg and comparable to ondansetron 8 mg for preventing postoperative nausea and vomiting after laparoscopic surgery.
Answers are grounded in this paper and cite their sources.
Positions ramosetron as a viable alternative to high-dose ondansetron for postoperative nausea.
Objective We conducted a systematic literature search and meta-analysis to identify randomized controlled trials (RCTs) comparing the efficacy and safety of ramosetron versus ondansetron for the prevention of postoperative nausea and vomiting (PONV; PON and POV, respectively) in patients undergoing laparoscopic surgery. Methods The electronic databases PubMed, EMBASE, Web of Science, and Cochrane Library were searched up to March 2019 to identify relevant studies. Results The final pooled analysis included 6 RCTs and revealed that postoperative treatment with ramosetron at 24 to 48 hours after surgery significantly reduced the incidence of PON and POV relative to treatment with ondansetron. In a subgroup analysis, ramosetron 0.3 mg tended to reduce PON (0–2 hours) and POV (24–48 hours) more effectively than ondansetron 4 mg. However, no statistical difference was observed between ramosetron 0.3 mg and ondansetron 8 mg in terms of the reduction of PON or POV during any time interval within the first 48 hours after surgery. Conclusions Our results indicate that ramosetron 0.3 mg is superior to ondansetron 4 mg and comparable to ondansetron 8 mg for PONV prophylaxis after laparoscopic surgery.
No takes yet. Share an insight, caveat, or question.
Li et al. (2019) conducted a meta-analysis in Postoperative nausea and vomiting (PONV). Ramosetron vs. Ondansetron (4 mg or 8 mg) was evaluated on Incidence of postoperative nausea and vomiting (PONV). Ramosetron was superior to ondansetron and comparable to ondansetron for the prevention of postoperative nausea and vomiting after laparoscopic surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: